Oncology drug development is becoming more complex, and bioanalysis can no longer be treated as simple drug measurement.

Sponsored by Leucentra, https://leucentra.com/

Inspired by science, empowered by IT. Leucentra helps life science and healthcare organizations evaluate, implement, and get more value from technology that supports innovation.

In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe speak with Dr. Lakshmi Amaravadi, Head of Oncology Bioanalysis at AstraZeneca, live from AAPS PharmSci 360 in San Antonio.

Dr. Amaravadi unpacks why biomarker validation is not one-size-fits-all, how context of use should guide scientific decision making, and why fit-for-purpose validation matters in modern oncology drug development.

The conversation explores:

00:00 Why oncology bioanalysis is becoming more complex

02:12 FDA biomarker validation guidance and industry response

04:27 What “fit for purpose” means in practice

06:38 PK assay validation vs biomarker assay validation

07:52 What drives Dr. Amaravadi’s work in translational science

10:48 Why validation is not a checkbox exercise

12:19 Advice for young scientists entering bioanalysis

15:12 Why oncology drug development is uniquely complex

18:17 ADCs, bispecifics, T-cell engagers, and conditional T-cell engagers

19:38 Why bioanalysis now requires understanding biology

20:46 Dr. Amaravadi’s path from molecular biology to bioanalysis

24:34 Critical reagent management in complex oncology assays

26:42 Validation, qualification, and context of use

29:03 Final thoughts from AAPS PharmSci 360

This episode is especially relevant for scientists, bioanalytical leaders, translational researchers, clinical pharmacologists, oncology development teams, biomarker scientists, and anyone working at the intersection of drug development, assay validation, and precision medicine.

Dr. Amaravadi discusses how oncology programs now involve ADCs, bispecifics, T-cell engagers, conditional T-cell engagers, complex linkers, multiple measurable species, immunogenicity considerations, and biomarker strategies that require deeper biological understanding. As she explains in the episode, the future of oncology bioanalysis is not simply measuring what is present. It is understanding what the measurement means in the context of the biology and the development decision.

Follow BioTalk Unzipped for conversations with leaders in biotech, pharma, bioanalysis, clinical development, translational science, regulatory strategy, and the future of medicine.

Guest

Dr. Lakshmi Amaravadi

https://www.linkedin.com/in/lakshmi-amaravadi/

Hosts

Gregory Austin

https://www.linkedin.com/in/gregoryaustin1/

Dr. Chad Briscoe

https://www.linkedin.com/in/chadbriscoe/

Sponsor: Leucentra

Related Links

Celerion

https://www.celerion.com/